With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Initially launched in Europe, this new service gives customers access to a range of digital health services and medical professionals and is part of its Digital Access to Care Initiative
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
The order strengthens the company’s position in the East African market
Subscribe To Our Newsletter & Stay Updated
